Welcome to Pharmacosmos International
April 29, 2020

WHO releases new guidelines on iron deficiency

Read more
February 10, 2020

Pharmacosmos establishes new specialty pharmaceutical company Pharmacosmos Therapeutics, Inc. in the US

Read more
August 15, 2019

New Managing Director in Germany

Read more
July 8, 2019

Pharmacosmos Strengthens Leadership Team

Read more
February 8, 2019

Jacob Tolstrup elected new Chairman of the Board of Directors of Pharmacosmos

Read more
September 6, 2018

Monoferric(TM) (iron isomaltoside 1000 for injection) receives marketing approval from Health Canada

Read more
June 22, 2018

Heavy metal impurities found in 94 percent of tested injectable irons for piglets

Read more
November 30, 2017

Pharmacosmos Introduces Pharmaceutical Quality DEAE-Dextran

Read more
June 26, 2017

Pharmacosmos Enters into Agreement with Laboratoire Aguettant for Exclusive Commercialisation Rights to Monover® (iron isomaltoside) in France

Read more
April 6, 2017

Improved animal welfare and economy: More live-born baby pigs per litter

Read more
February 27, 2017

Pharmacosmos Enters into Exclusive Commercialization Agreement with Pfizer for Monofer® (iron isomaltoside) in Brazil

Read more
December 19, 2016

Nippon Shinyaku enters into a license agreement with Pharmacosmos on an intravenous iron therapy, Monofer® (iron isomaltoside 1000)

Read more
November 17, 2016

Monofer (iron isomaltoside) launched in India under brand names “ISOFER” and “JILAZO”

Read more
August 19, 2016

Pharmacosmos to initiate large-scale clinical study programme

Read more
August 15, 2016

Pharmacosmos launches new website on novel cryoprotectant Pentaisomaltose®

Read more
June 7, 2016

First ever hard endpoint trial with IV iron (Monofer®) in chronic heart failure

Read more
February 10, 2016

Pharmacosmos Chief Medical Officer appointed Adjunct Professor

Read more
December 15, 2015

Celebrating 50 years

Read more
April 17, 2015

Pharmacosmos introduces DEAE-Dextran

Read more
February 18, 2015

Pharmacosmos Enters into Agreement with Pfizer for Exclusive Commercialization Rights in Canada to Monofer®

Read more

Media

Click here for high resolution pictures for press usage.

 

© 2021 PHARMACOSMOS A/S
This website contains information on products which is targeted to a wide range of audiences outside US and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Monofer®, CosmoFer®, Diafer® and Uniferon® are registered trademarks of Pharmacosmos A/S. All rights reserved.
Privacy Notices Terms & Conditions

Pharmacosmos